Last reviewed · How we verify
Giant cell arteritis in adults — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Rinvoq | upadacitinib | AbbVie Inc. | JAK inhibitor | Janus kinase (JAK) enzymes, particularly JAK1 and JAK2 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- AbbVie Inc. · 1 drug in Giant cell arteritis in adults
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Giant cell arteritis in adults:
- Giant cell arteritis in adults treatment updates — RSS
- Giant cell arteritis in adults treatment updates — Atom
- Giant cell arteritis in adults treatment updates — JSON
Cite this brief
Drug Landscape (2026). Giant cell arteritis in adults — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/giant-cell-arteritis-in-adults. Accessed 2026-06-11.
Related
- Giant cell arteritis in adults full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing